New York, October 29, 2026 / PRNewswire / – Pomerantz LLP represents and is in charge of handling investor-related claims on behalf of Rafael Holdings, Inc (referred to as “Rafael” or “the Company”) ( NYSE : RFL ). The firm recommends that concerned investors contact Danielle Peyton at the email address [ email protected ] and by phone at 646-581-9980, extension 7980.

This investigation involves whether Rafael and some of its senior executives and/or directors have engaged in securities fraud or other illegal business practices.

On September 30, 2026, Rafael issued a press release announcing the top-line data on the efficacy and safety of the pivotal Phase 3 TransportNPC™ study ( CTD-TCNPC-301 ) conducted by its subsidiaries Cyclo Therapeutics and LLC. The study evaluated the performance of Trappsol Cyclo™ (hydroxypropyl-β-cyclodextrin for intravenous injection) in 94 patients with Niemann to Pick C disease ( NPC ). The press release stated that "the results did not achieve statistical significance at the primary endpoint."

Affected by this news, the stock price of Rafael fell by $0.71 per share on September 30, 2026, a decrease of 34.98%, closing at $1.32 per share.

Pomerantz LLP has offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, and is considered one of the leading law firms in the fields of corporate, securities, and antitrust class actions. The firm was founded by the late Abraham L and Pomerantz, the latter being regarded as a pioneer in the field of class action litigation. Pomerantz states that, more than 85 years later, it continues its founding tradition by fighting for the rights of victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The firm has represented class action members in obtaining compensation awards totaling millions of dollars. For more details, please refer to www.pomlaw.com.

Lawyer advertisement. Past results do not guarantee similar outcomes.

Contact Information: